Today's Sponsored Feature is part of your subscription to the daily AAP SmartBrief. This feature, produced by SmartBrief and a select group of sponsors, highlights issues, products and services of interest to pediatricians and other child health professionals. It also allows for continued free delivery of AAP SmartBrief. Thank you for your interest.

-- The AAP SmartBrief Team

Collaborative Research Seeks to Transform AML Care

National research on Gemtuzumab Ozogamicin, or Mylotarg®, is having a ripple effect on future AML research and treatment. The randomized Phase III COG trial, under the direction of Alan Gamis, MD, MPH, recent past AML Disease Scientific Committee Chair for COG, looked into the benefits of adding Mylotarg to standard chemotherapy. Results indicate Mylotarg improves event-free survival by reducing relapse risk.

Learn more here.
Breaking the Language Barrier Transforms Treatment

Maneuvering complex medical conditions and treatment can be a daunting task, especially when caregivers and patients speak different languages. Children's Mercy Kansas City is helping to address the unique needs of Spanish-speaking patients with a Spanish-Speaking Hematology/Oncology Clinic.

Learn more here.
Children's Mercy Kansas City is an independent, 354-bed pediatric health system, serving half a million patients each year from across the country. Children's Mercy has been ranked by U.S. News & World Report as one of "America's Best Children's Hospitals" and received Magnet recognition three times for excellence in nursing services.

In affiliation with the University of Missouri-Kansas City, our faculty of nearly 600 pediatric subspecialists and researchers are actively involved in clinical care, pediatric research, and educating the next generation of pediatric subspecialists.

Each year, the Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation provides comprehensive care to nearly 2,000 children with childhood cancers, sickle cell disease, hemophilia and other blood disorders, with survival rates frequently above national averages. At any given time, the Division is participating in 80-100 clinical and laboratory trials, including several national trials led by its own investigators. As the primary pediatric cancer provider and the only NCI Children's Oncology Group institution in the Midwest Cancer Alliance, the Division is the pediatric partner for the National Cancer Institute-designated University of Kansas Cancer Center. The Division also has received accreditation from the American College of Surgeons Commission on Cancer for excellence in providing quality care to cancer patients.
Testing a New Weapon against Neuroblastoma
A clinical trial at Children's Mercy Kansas City is using a pair of cell-based immunotherapies to enhance neuroblastoma treatment. The trial adds a specialized bone marrow transplant to previous investigations that use chimeric T-cell receptors to target GD2 on the surface of neuroblastoma cells.

Learn more here.
  • Survivors of childhood cancer treatments may have decreased arterial health
    Chemotherapy-treated survivors of pediatric leukemia and other cancers had a greater chance of experiencing a decline in arterial function compared with youths without cancer, according to a study presented at an American Heart Association meeting. Among leukemia survivors, researchers found a 9% decline in arterial health following chemotherapy. "Given this increased risk, children who survive cancer should make lifestyle changes to lower their cardiovascular risk," study author Donald Dengel said. Reuters (11/17), HealthDay News (11/18)
  • Frailty linked to increased health, mortality risks in childhood cancer survivors
    Childhood cancer survivors who were frail had a greater likelihood of suffering from a chronic illness and were 2.6 times more likely to die than survivors who were not frail, a study showed. Pre-frailty and frailty were more prevalent among survivors compared with people without a history of cancer, which indicates that cancer survivors may be experiencing accelerated aging, researchers reported in the Journal of Clinical Oncology. (11/18)
  • Survivors of childhood ALL are more prone to cognitive problems
    U.S. researchers conducted neurocognitive tests on 567 adult survivors of childhood acute lymphoblastic leukemia and found that between 28.6% and 58.9% of them had some form of cognitive impairment. Participants reported a progressive increase in behavioral problems yearly after diagnosis. The findings appear in the Journal of Clinical Oncology. (11/4)
  • Pediatric-onset lupus linked to increased cancer risk
    Children diagnosed with lupus were slightly more likely to develop cancer later in life, particularly hematological cancers, compared with the general population, McGill University researchers wrote in the journal Arthritis Research & Therapy. Among lupus patients, the highest cancer occurrence rate was during the 10 to 19 years following lupus diagnosis, according to the study. (12/1)
What is this?A Sponsored Feature is an advertorial that includes valuable content provided by the sponsor and editorial materials from SmartBrief's archives. This Sponsored Feature does not represent an endorsement by the AAP or SmartBrief, Inc. of the products and services offered. If you unsubscribe from this Sponsored Feature, you will not be unsubscribing from all other editions of the AAP SmartBrief.
Subscriber Tools:
Sign up for AAP SmartBrief | Send Feedback | Email this brief | Unsubscribe from AAP SmartBrief Sponsored Features
Advertising with SmartBrief:Associate Healthcare Publisher Aaron Kern 202-407-7866
Mailing Address:SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®  Legal Information.